Commercially available drugs that target IL-1, including anakinra, a recombinant human IL-1 receptor antagonist, and canakinumab, a human monoclonal antibody targeting IL-1β, have been investigated in the treatment of asthma [39]. The gene discussed is IL1A; the disease is asthma.